 Yesterday Trevi Therapeutics Incs NASDAQ: TRVI Phase 2b3 trial PRISM evaluating Haduvio nalbuphine ER for prurigo nodularis PN successfully met the key primary and secondary endpoints. Needham writes that Haduvio had a quick onset of action, reaching stat sig at. 